Egetis Therapeutics

Board/Management Information • Oct 20, 2020

PRESS RELEASE PledPharma AB Stockholm October 20, 2020

Nomination Committee appointed for the 2021 Annual General Meeting in PledPharma

Stockholm, October 20, 2020. The Chairman of PledPharma AB has established a Nomination Committee for the Annual General Meeting, which is planned to be held on April 29, 2021. The Nomination Committee is composed of members appointed by the three largest shareholders in terms of voting rights, that have accepted the invitation to join the committee.

The following members have been appointed by the subsequent shareholders:

Cidro Förvaltning AB: Peter Lindell Nortal Investments AB: Staffan Persson Fjärde AP-fonden: Jannis Kitsakis

In total, the Nomination Committee represents approx. 31% of the total number of shares and votes in the company. All representatives are independent in relation to the company and its executive management. Staffan Persson and Jannis Kitsakis are also independent in relation to Cidro Förvaltning AB, which is the largest shareholder in the company in terms of votes.

The Nomination Committee has elected Peter Lindell as chairman. Håkan Åström, Chairman of PledPharma have been nominated to co-opt to the Nomination Committee.

PledPharma AB (publ) signed an agreement to acquire all outstanding shares in Rare Thyroid Therapeutics International AB (RTT) on October 5, 2020. The transaction is expected to be completed on November 3, 2020.

As a part of the share purchase price the former shareholders in RTT will receive 63,773,345 new shares in PledPharma trough an issue of Consideration Shares.

On the occasion of the acquisition of RTT, PledPharma carries out a rights issue of a maximum of 38,238,085 shares. The subscription period is 9 November to 23 November 2020.

The composition of the three largest shareholders will be amended due to the issue of the Consideration shares and the Rights Issue. Therefore, the composition of the future Nomination Committee will also change to reflect the new ownership. PledPharma intends to return with information on the composition of the new Nomination Committee after the new ownership has been registered.

The Committee's assignment is to present proposals regarding Chairman and other members of the, as well as remuneration to the Board´s members, to the Annual General Meeting (AGM). The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals to the process to appoint the Nomination Committee for the AGM in 2022.

Shareholders who wish to submit proposals to the Nomination Committee can do so by email: hakanastrom@aol.com

For further information, please contact:

Marie-Louise Alamaa, Interim CFO Tel. 070 861 88 42 marie-louise.alamaa@pledpharma.se

About PledPharma

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The drug candidate Aladote® is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed, and the design of the next study is being finalised. Aladote® has been granted Orphan Drug

Designation in the US. The Phase III POLAR program for the drug candidate PledOx® was prematurely stopped in Q2 2020. Results from POLAR program will determine if further development of PledOx is warranted via strategic partnership/s and is expected to be announced in Q4 2020. PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see http://www.pledpharma.com/